Search results for "Conservation"

showing 10 items of 2328 documents

A single key-odorant accounts for the pheromonal effect of rabbit milk : Further test of the mammary pheromone's activity against a wide sample of vo…

2003

In the rabbit, lactating females emit a volatile compound in milk, the mammary pheromone (MP), that triggers rooting for the nipple and its grasping in pups. Previous studies have shown that the MP seems to act selectively, in terms both of intensity and quality. Here, we aimed to add new evidence to these properties of the MP. Newborn rabbits (n=825) were submitted to an oral activation test allowing to measure their searching/grasping responses towards different stimuli. In Experiment 1 we assessed whether pups respond to the MP in an intensity-dependent manner. In Experiment 2 we assessed the activity of 20 volatiles previously identified in rabbit milk, other than the MP, which were nev…

medicine.medical_specialtyActivation test[SCCO.NEUR]Cognitive science/Neuroscience05 social sciences[SCCO.NEUR] Cognitive science/NeuroscienceRabbit (nuclear engineering)BiologyChemical communicationBiochemistryAndrology03 medical and health sciences0302 clinical medicineEndocrinologyNature ConservationInternal medicine[ SCCO.NEUR ] Cognitive science/NeurosciencemedicinePheromone0501 psychology and cognitive sciences050102 behavioral science & comparative psychology030217 neurology & neurosurgeryEcology Evolution Behavior and Systematics
researchProduct

Review and update on drugs related to the development of osteonecrosis of the jaw

2019

Conflict of interest Conclusions of the working group on “New drugs related to the de-velopment of osteonecrosis of the jaw”. Spanish Society of Cranio-mandibular Dysfunction and Orofacial Pain and Spanish Society of Oral Medicine SEDCYDO-SEMO joint International Meeting: 30th SEDCYDO annual meeting & 15th SEMO Congress. Bilbao (Spain); June, 2019. [EN] Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious adverse effect of cer-tain drugs, of which bisphosphonates are the most widely known. This pathology is also associated with other medications such as the biologic antiresorptive agent, denosumab and some antiangiogenics such as sunitinib, bevacizumab or a…

medicine.medical_specialtyBevacizumabReviewMRONJ03 medical and health sciencesantiresorptives0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectGeneral DentistrybisphosphonatesAfliberceptBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industrySunitinibOsteonecrosis030206 dentistryEvidence-based medicinemedicine.disease:CIENCIAS MÉDICAS [UNESCO]osteonecrosis of the jawantiangiogenicsDenosumabOtorhinolaryngologyPharmaceutical PreparationsUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis

2011

Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered…

medicine.medical_specialtyBone Density Conservation AgentBone densityOsteoporosisAlternative medicineadherence; osteoporosis; treatment algorithm; bone density; medication possession ratio; bisphosphonatesMedication AdherenceClinical ProtocolsCost of IllnessTreatment algorithmmedicineHumansBisphosphonatePharmacology (medical)DosingClinical ProtocolAdverse effectMED/01 - STATISTICA MEDICAOsteoporosis PostmenopausalAdherence bisphosphonates bone density medication possession ratio osteoporosis treatment algorithmMedication possession ratioPharmacologyBone Density Conservation Agentsbusiness.industryOsteoporosiGeneral Medicinemedicine.diseaseAlgorithmCost of IllneClinical trialBone Density Conservation AgentsTreatment OutcomeZoledronic acidAdherenceAdherence; Bisphosphonates; Bone density; Medication possession ratio; Osteoporosis; Treatment algorithm; Algorithms; Bone Density Conservation Agents; Clinical Protocols; Cost of Illness; Female; Humans; Osteoporosis; Osteoporosis Postmenopausal; Treatment Outcome; Medication Adherence; Pharmacology; Pharmacology (medical)Physical therapyOsteoporosisFemaleBone densitybusinessAlgorithmsHumanmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Radiodensitometric study for evaluation of bone mineral density around dental implants after zoledronic acid treatment in ovariectomized rats

2017

Background The purpose of this study was to evaluate the effects of intravenous zoledronic acid applied systemically on osseointegration of dental implants and the surrounding bone mineral density (BMD) in the ovariectomized rats. Material and Methods 36 rats were divided into three groups: control (CTRL), ovariectomy (OVX), and ovariectomy-zoledronic acid (OVX/ZOL). The rats in the CTRL group underwent sham surgery, while rats in OVX and OVX / ZOL group underwent ovariectomy. After 12 weeks, rats from OVX / ZOL were injected with 0.04 mg/kg ZOL intravenously once a week for 6 weeks. The rats from CTRL and OVX groups were injected with 0.9% NaCl. Implants were placed in the left tibia. Afte…

medicine.medical_specialtyBone densityOvariectomyDentistryZoledronic AcidOsseointegration03 medical and health sciences0302 clinical medicineAbsorptiometry PhotonBone DensityOsseointegrationInternal medicineMedicineAnalysis softwareAnimalsTibiaRats WistarGeneral DentistryBone mineralDental ImplantsBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchSham surgeryImidazoles030206 dentistry:CIENCIAS MÉDICAS [UNESCO]RatsZoledronic acidEndocrinologyOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASOvariectomized ratSurgeryFemaleOral Surgerybusinesshormones hormone substitutes and hormone antagonistsmedicine.drugMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis

2007

Recently, jawbone osteonecrosis has been largely reported as a potential adverse effect of bisphosphonate (BP) administration. Because of the peculiar pharmacokinetic and pharmacodynamic features of the BF (mainly for i.v. administration), their efficacy and large use, some major issues have to be taken into account extendedly both by oncologists and by dentists: 1) therapeutic dental protocol for patients with diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ); 2) dental strategies for patients in former or current i.v. BF treatment and in absence of BRONJ signs; 3) strategies for patients before i.v. BF treatment. Clinical features and guidelines for the management of th…

medicine.medical_specialtyBone diseasemedicine.medical_treatmentDentistryBone NeoplasmsJaw neoplasmPatient Education as TopicmedicineHumansDental Restoration PermanentIntensive care medicineAdverse effectbisphosphonates metastatic bone diseaseBone Density Conservation AgentsDiphosphonatesbusiness.industrySurrogate endpointAdvanced stageOsteonecrosisHematologyBisphosphonatemedicine.diseaseJaw NeoplasmsOncologybusinessOsteonecrosis of the jawAnnals of Oncology
researchProduct

Male breast cancer: Modified radical mastectomy or breast conservation surgery? A case report and review of the literature

2016

INTRODUCTION: Male breast cancer (MBC) is a rare disease that accounts for <1% of breast cancer cases. The most common treatment is modified radical mastectomy (MRM). Recently, breast conservative surgery (BCS) is getting popular for MBC treatment. We report a case and reviewed the literature to investigate whether emerging BCS can be considered as an alternative of a more radical surgery. PRESENTATION OF CASE: A 46 y.o. patient, presented with a painless left breast lump over a period of six months. The patient underwent a quadrantectomy at another institution. Pathology revealed an intraductal carcinoma in close proximity to the margins of excision. Adjuvant hormonal therapy was proposed …

medicine.medical_specialtyBreast; Breast conserving surgery; Case report; Chest wall reconstruction; Male breast cancer; Mastectomy; Surgerymedicine.medical_treatmentSettore MED/19 - Chirurgia PlasticaModified Radical Mastectomy03 medical and health sciences0302 clinical medicineBreast cancerBreast conserving surgeryCase reportmedicineBreast-conserving surgeryBreastRadical surgeryskin and connective tissue diseasesMastectomyBreast conservationbusiness.industryGeneral surgerymedicine.diseaseSurgeryMale breast cancer030220 oncology & carcinogenesisMale breast cancerSurgerybusinessChest wall reconstruction030217 neurology & neurosurgeryMastectomyRare disease
researchProduct

Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover

2005

We studied clinical performance of serum TRACP 5b and other bone turnover markers, including S-CTX, U-DPD, S-PINP, S-BALP, and S-OC, for monitoring alendronate treatment. TRACP 5b had higher clinical sensitivity, area under the ROC curve, and signal-to-noise ratio than the other markers. INTRODUCTION: The purpose of this study was to compare the clinical performance of serum TRACP 5b (S-TRACP5b) with that of other markers of bone turnover in the monitoring of alendronate treatment. MATERIALS AND METHODS: This double-blinded study included 148 healthy postmenopausal women that were randomly assigned into two groups: one receiving 5 mg alendronate daily (n=75) and the other receiving placebo …

medicine.medical_specialtyDeoxypyridinolineEndocrinology Diabetes and MetabolismAcid PhosphataseUrologyPlaceboBone resorptionBone remodelingchemistry.chemical_compoundDouble-Blind MethodOsteogenesisInternal medicinemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineVitamin DAlendronateBone Density Conservation AgentsReceiver operating characteristicbiologyTartrate-Resistant Acid Phosphatasebusiness.industryAlendronic acidMiddle AgedIsoenzymesPostmenopauseEndocrinologychemistryOsteocalcinbiology.proteinCalciumFemaleDrug MonitoringbusinessBiomarkersmedicine.drugJournal of Bone and Mineral Research
researchProduct

Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study

2006

None of the available osteoporosis therapies have been shown to completely abolish the risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them. This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly related to poor compliance and lack of supplementation with calcium and vitamin D. Introduction: Osteoporotic fracture is one of the most important public health concerns among the elderly. Currently available therapies have been shown to significantly decrease the …

medicine.medical_specialtyFracture riskEndocrinology Diabetes and MetabolismOsteoporosisIncidence; FRACTURETreatment resistancelaw.inventionCalcium and vitamin D intake Fracture risk Osteoporosis Treatment compliance Treatment resistancecalcium and vitamin d intake; fracture risk; osteoporosis; treatment compliance; treatment resistanceFractures BoneRandomized controlled trialRisk FactorslawInternal medicineCalcium and vitamin D intakemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineRaloxifeneVitamin DAgedRetrospective StudiesAlendronateBone Density Conservation Agentsbusiness.industryIncidenceIncidence (epidemiology)Etidronic AcidRetrospective cohort studyMiddle Agedmedicine.diseaseCalcium and vitamin D intake Fracture incidence Fracture risk Osteoporosis Treatment compliance Treatment resistanceFRACTUREFracture incidenceSurgeryItalyRaloxifene HydrochlorideRisedronic acidOsteoporosisFemaleObservational studyTreatment compliancebusinessRisedronic Acidmedicine.drug
researchProduct

The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Prot…

2021

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents, and it is also a potentially painful and debilitating condition. To date, no specific studies have prospectively evaluated the efficacy of its treatment and no robust standard of care has been established. Therefore, a systematic review (2007–2020) with a pooled analysis was performed in order to compare MRONJ surgical techniques (conservative or aggressive) versus combined surgical procedures (surgery plus a non-invasive procedure), where 1137 patients were included in the pooled analysis. A statistically significant difference in the 6-month improvement rate, comp…

medicine.medical_specialtyHealth Toxicology and Mutagenesismedicine.medical_treatmentONJReviewsurgerymedicineHumansAdverse effectONJ Osteonecrosis Staging Surgery Therapy TreatmenttherapyONJ; Osteonecrosis; Staging; Surgery; Therapy; Treatment; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Humans; Bone Density Conservation AgentsDiphosphonatesBone Density Conservation Agentstreatmentbusiness.industryosteonecrosisSignificant differenceBlood componentRPublic Health Environmental and Occupational HealthstagingSurgical proceduresmedicine.diseaseSurgeryPooled analysisImprovement rateMedicineBisphosphonate-Associated Osteonecrosis of the JawOsteonecrosis of the jawbusinessAdjuvantInternational Journal of Environmental Research and Public Health
researchProduct

Complex regional pain syndrome: An optimistic perspective.

2014

Complex regional pain syndrome (CRPS) presents with clinical symptoms that can no longer be explained by the initial trauma, including pain, sensory, motor, and trophic symptoms, and impairment of autonomic control of the limb. These symptoms spread distally and go beyond single nerve innervation territories. Typically, the symptoms change through the course of CRPS as a result of the varying pathophysiology. Diagnosis is made clinically after the rigorous elimination of other possible causes, and 3-phase bone scintigraphy can be a useful tool for confirming CRPS. In acute stages, inflammatory symptoms prevail and should be treated with anti-inflammatory agents (steroids), bisphosphonates, …

medicine.medical_specialtyImagery PsychotherapyImplosive TherapyPainMotor imageryOccupational TherapyNeuroplasticitymedicineHumansKetamineGlucocorticoidsPhysical Therapy ModalitiesAnalgesicsmedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industrySensory lossmedicine.diseaseComorbidityComplex regional pain syndromeBone scintigraphyAutonomic Nervous System DiseasesHyperalgesiaHyperalgesiaPhysical therapyKetamineNeurology (clinical)medicine.symptombusinessComplex Regional Pain Syndromesmedicine.drugNeurology
researchProduct